RESEARCH ARTICLE

Lunasin attenuates obesity-related inflammation in RAW264.7 cells and 3T3-L1 adipocytes by inhibiting inflammatory cytokine production

Chia-Chien Hsieh*, Mei-Jia Chou, Chih-Hsuan Wang

Department of Human Development and Family Studies, National Taiwan Normal University, Taipei, Taiwan

* hsieh@ntnu.edu.tw

Abstract

Obesity has become a major threat to public health and is accompanied by chronic low-grade inflammation, which leads to various pathological developments. Lunasin, a natural seed peptide, exhibits several biological activities, such as anti-carcinogenesis, anti-inflammatory, and antioxidant activities. However, the mechanism of action of lunasin in obesity-related inflammation has not been investigated. The aim of this study was to explore whether lunasin could reduce the inflammation induced by obesity-related mediators in RAW264.7 cells and 3T3-L1 adipocytes and whether it could attenuate the crosstalk between the two cell lines. RAW264.7 cells were cultured in leptin-containing medium, adipocyte-conditioned medium (Ad-CM), or co-cultured with 3T3-L1 cells to mimic the physiology of obesity. The data showed that the secretion of pro-inflammatory cytokine interleukin-1β (IL-1β) was inhibited by lunasin after leptin activation of RAW264.7 cells. In addition, lunasin decreased monocyte chemoattractant protein-1 (MCP-1) and IL-1β secretions in the Ad-CM model. Cytokine MCP-1, IL-6, tumor necrosis factor (TNF)-α, and IL-1β secretions were significantly decreased by leptin or Ad-CM plus lipopolysaccharide stimulation. Subsequently, the co-culture of the two cells refined the direct relation between them, resulting in apparently increased MCP-1, and decreased IL-6 levels after lunasin treatment. In 3T3-L1 adipocytes, lunasin also exhibited anti-inflammatory property by inhibiting MCP-1, plasminogen activator inhibitor-1, and leptin productions stimulated by (TNF)-α, lipopolysaccharide, or RAW264.7 cell-conditioned medium. This result revealed that lunasin acts as a potential anti-inflammatory agent not only in macrophages but also in adipocytes, disrupting the crosstalk between these two cells. Therefore, this study suggests the intake of lunasin from diet or as a supplement, for auxiliary prevention or therapy in obesity-related inflammatory applications.
Introduction

Statistical estimation by the World Health Organization in 2014 indicated that 39% of the adults worldwide were overweight and 13% were clinically obese, approximating to a total of 2.1 billion people worldwide [1]. Adipose tissue plays a major endocrine role of secreting various adipokines that affect the physiology [2]. However, excessive accumulation of energy transfer to adipocytes due to hyperplasia and hypertrophy is termed as obesity. Obesity is characterized by low-grade inflammation of the microenvironment with infiltration by various immune cells, such as leukocytes, granulocytes, monocytes/macrophages, lymphocytes, and dendritic cells, which overproduce a series of pro-inflammatory and pro-atherogenic mediators [3, 4]. Therefore, obesity initiation and development are linked to several obesity-associated diseases, such as cardiovascular complications, metabolic disorders [4], and several types of cancers [5, 6].

In obesity, the main players in the systemic chronic inflammation are the increased numbers of pro-inflammatory macrophages and production of deregulated hormones and cytokines, such as monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-α (TNF-α), by the adipose tissue [2]. Particularly, this inflammation process involves regulation of various cells stimulating the production of recruited chemokines and active cytokines, to modulate the signaling pathways of energy and lipid metabolism, insulin resistance, cell proliferation in the microenvironment, and epigenetic genes expression [4].

Inflammation, as a pathophysiological condition, is involved in the development of many chronic diseases. A study has reported the potential benefits of supplementary diets and micronutrients that modulate the local and systemic chronic inflammation [7]. Therefore, food components are important mediators that participate in pro-inflammatory or anti-inflammatory reactions. Recently, several studies have demonstrated that food can be scored according to their inflammatory capacity, termed as dietary inflammatory index, which shows a close correlation of diet with inflammation and cardio-metabolic diseases [8].

Lunasin is a 43 amino acid-long natural peptide that was first identified in soybean [9], several grains, and herbal plants [10]. This peptide has been shown to exhibit biological activities against diseases, such as cancer, cardiovascular diseases, and immune disorders, in both in vitro and in vivo studies [10, 11]. In 2009, its anti-inflammatory property was first proposed. Moreover, it also shows antioxidant activity. Both these properties may contribute to its chemopreventive actions [12]. The anti-inflammatory property of lunasin has been demonstrated in RAW264.7 cells stimulated by lipopolysaccharide (LPS), resulting in the inhibition of pro-inflammatory cytokine production [12], possibly by blocking of the nuclear factor-κB (NF-κB) signaling pathway in RAW264.7 cells [13, 14] and by the down-regulation of Akt-mediated NF-κB activation in active THP-1 macrophages [15]. Lunasin leads to reduction in the inflammatory reaction induced by macrophages, through endocytic mechanisms involving clathrin-coated vesicles and macropinosomes [16].

Obesity provides an inflammatory microenvironment, which is favorable to metabolic complications and even tumorigenesis. Based on this evidence, dietary compounds have a major role in inflammation-related outcomes [7]. It is particularly intriguing to understand how lunasin operates in relation to the adipose microenvironment. However, only a few studies have explored natural compounds used to disrupt the crosstalk between macrophages and adipocytes, applying them to obesity-related inflammatory disorders. In the present study, we investigated the anti-inflammatory property of lunasin on RAW264.7 cells and 3T3-L1 adipocytes and set up models to explore their crosstalk. As the anti-inflammatory property of lunasin linked to adipose tissue inflammation holds great promise as a candidate for future therapeutic intervention, a better understanding of its underlying actions is required.
Materials and methods

Cell culture and reagents

Mouse RAW264.7 macrophages and 3T3-L1 fibroblasts were kindly provided by Dr. Tsai and Dr. Lin of National Taiwan Normal University and National Taiwan University (Taipei, Taiwan), respectively. RAW264.7 and 3T3-L1 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Caisson, Smithfield, UT, USA), containing fetal bovine serum (FBS; Genetrex, Las Vegas, NV, USA), 10% heat-inactivated calf serum (BS, Gibco, Grand Island, NY, USA), and 1% penicillin/streptomycin/amphotericin B (Caisson), and were incubated at 37˚C in a humidified incubator with 5% CO₂ atmosphere. These two cells from murine were chosen referred to many co-culture or conditional medium models in the present study. Cells from the same species are reasonable and easy to handle in the experimental operation. Lunasin, a 43 amino acid-long peptide with the sequence SKWQHQDSCRKQLQGVNTFCRCHIMEKI QGRGDDDDDDDDD, was chemically synthesized by KaiJie Bio-pharmaceutical Company (Chengdu, China). The purity of this peptide was greater than 95%.

Cell viability assay

RAW264.7 cells were seeded at a density of $1 \times 10^4$ cells/well in 96-well plates (Becton Dickinson, Franklin Lakes, NJ, USA) and were treated with various concentrations of lunasin, leptin (recombinant mouse leptin protein, R&D Systems, Minneapolis, MN, USA), and LPS (Sigma, St. Louis, MO, USA). After 24 h of the treatments, cells were incubated with 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) solution for 3 h at 37˚C, after which the supernatant was aspirated and dimethyl sulfoxide was added to solubilize the formazan crystals. The spectrophotometric absorbance at 540 nm was determined by a microplate reader (BioTek, Winooski, VT, USA). The cell viability was calculated as a percentage of control, which was considered as 100%, according to the formula: $(A_{\text{sample}} - A_{\text{blank}}) / (A_{\text{control}} - A_{\text{blank}}) \times 100$.

Differentiation of 3T3-L1 preadipocytes into adipocytes

The 3T3-L1 fibroblasts were differentiated to adipocytes as described previously [17]. Briefly, 3T3-L1 fibroblasts were seeded at $3 \times 10^4$ cells/well in 24-well plates (Becton Dickinson) containing 10% FBS/DMEM. After the cells reached full confluence, differentiation was induced by using medium I: 25 mM glucose, 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 0.2 μM dexamethasone (Sigma), and 10 μg/mL insulin (Sigma) in 10% FBS medium, for the first 4 days and then by medium II: 25 mM glucose, 10 μg/mL insulin, and 10% FBS medium for 13 days. The medium was replaced by fresh medium II every 3 days to promote the maturation of adipocytes. At the end of the differentiation, the cells exhibited the adipocyte phenotype and they were then designed for further analyses.

Culture of RAW264.7 cells in obesity-related inflammatory models

To test the effects of LPS, leptin, and adipocyte-conditioned medium (Ad-CM) on RAW264.7 cell growth and adipokine secretion, serial doses of the treatments were added to the cells. Cell numbers were counted using the MTT assay, and MCP-1 level was analyzed by ELISA. Then, the obesity-related inflammatory models were set up for further in vitro experiments.

Leptin-induced adipocyte inflammation. Cells were treated with serial doses of leptin or leptin plus 100 ng/mL LPS for 24 h. MCP-1 production was analyzed in the supernatant to find the optimal stimulated condition. Then, cells were treated with 1, 10, and 50 μM of...
Lunasin and were activated by 200 ng/mL leptin, 100 ng/mL LPS, or a combination of both, for 24 h. Culture supernatants were collected for cytokine analysis by ELISA.

**Culture of RAW264.7 cells in Ad-CM.** Ad-CM was generated according to the previous protocol [17], the 3T3-L1 adipocytes differentiated on day 12, the medium was replaced by 10% FBS/DMEM for 24 h, and then the supernatant named Ad-CM was collected for subsequent in vitro study. RAW264.7 cells were seeded at 2×10^4 cells/well in a 48-well plate, treated with various doses 1, 10, and 50 μM of lunasin, with or without LPS activation, and were cultured in 25% Ad-CM and 75% medium with 10% FBS for 24 h to mimic the environment of adipocytes around the macrophages. Culture supernatants were collected for adipokine analysis by ELISA.

**Co-culture of 3T3-L1 adipocytes with RAW264.7 cells.** To mimic the physiological environment where obesity triggers macrophage infiltration, the macrophages and adipocytes were co-cultured in a transwell culture system. The 3T3-L1 cells were seeded in a 24-well plate in the lower compartment of a transwell culture system (0.4 μm pore size; Costar, Kennebunk, MA USA) and differentiated into adipocytes until day 13. The RAW264.7 cells were seeded at 4×10^4 cells/well in the upper chamber of the transwell. Then, both cells were put together in the co-culture system maintained in 10% FBS/DMEM and treated with 10 and 50 μM lunasin for 24 h. Culture supernatants were collected and stored at −20°C for cytokine assay.

**3T3-L1 adipocyte inflammatory models**

**LPS- and TNF-α-induced adipocyte inflammation.** 3T3-L1 cells were seeded at 3×10^4 cells/well in a 24-well plate for differentiation into adipocytes. On day 13, 3T3-L1 adipocytes were treated with various doses 5, and 25 μM of lunasin and were stimulated by 1000 ng/mL LPS or 10 ng/mL TNF-α (PeproTech, Rocky Hill, NJ, USA) in 1% FBS/DMEM simultaneously at the same time for 24 h. Culture supernatants were collected for inflammatory cytokine and adipokine analysis by ELISA.

**RAW264.7 Cell-conditioned Medium (RAW-CM)-induced adipocyte inflammation.** RAW264.7 cells were plated at a density of 5×10^5 cells/well in 24-well plates containing 10% FBS/DMEM, overnight. The cells were stimulated with 100 ng/mL LPS in 1% FBS/DMEM for 24 h, and the supernatants were collected and centrifuged to remove cell debris, for subsequent in vitro studies. 3T3-L1 cells were treated with various doses 5, and 25 μM of lunasin and were cultured in 50% RAW-CM containing 1% FBS/DMEM for 24 h. Culture supernatant was collected for cytokine and adipokine assay.

**Determination of cytokine and adipokine production by ELISA**

RAW264.7 and 3T3-L1 cells were seeded at 2×10^4 cells/well in a 48-well plate and 3×10^4 cells/well in a 24-well plate, respectively, overnight. Cells were treated with lunasin using various models for 24 h. Culture supernatants were collected and cytokines, such as IL-6, MCP-1, leptin, adiponectin, and plasminogen activator inhibitor-1 (PAI-1), were analyzed by ELISA, according to the manufacturer’s protocols (R&D Systems). In brief, capture antibodies, cultured supernatants, detection antibodies, streptavidin conjugated horseradish-peroxidase were processed on the plate in order, and the color subtract tetramethylbenzidine (R&D Systems) was used. The absorbance was measured and the concentration was calculated according to the standard.

**Statistical analysis**

The results were analyzed from at least three independent experiments and presented as mean ± standard error of mean (SEM). Differences between the groups were analyzed by one-
way ANOVA, followed by least significant difference (LSD) test using IBM Statistical Product and Service Solutions (SPSS) version 19. P-value less than 0.05 was considered statistically significant.

Results

Experimental design and basal conditions

To mimic the physiological environment of obesity associated with inflammation due to macrophage infiltration, three in vitro models: 1) leptin-treated macrophages, 2) Ad-CM-treated macrophages, and 3) co-culture of adipocytes and macrophages, were built to study the effect of lunasin on the obesity-related inflammatory reaction in RAW264.7 macrophages (Fig 1A).

Treatment with various concentrations of lunasin (0.2 to 200 μM) did not affect the growth of RAW264.7 cells (Fig 1B), suggesting that lunasin was a safe and non-toxic natural component. Subsequently, the effect of LPS treatment (10 to 1000 ng/mL) on RAW264.7 cells was tested using MTT assay, to confirm that the following effects were not due to changes in the cell numbers (Fig 1C). MCP-1 secretion increased with rise in LPS dosage, and this production saturated on activation with 500 ng/mL LPS (Fig 1D). A middle dose of 100 ng/mL LPS, which causes mild activation of macrophages, was used as a condition for future in vitro experiments.

Lunasin inhibited inflammatory cytokine production in leptin-conditioned RAW264.7 cells

Several studies have demonstrated the significantly high level of leptin in obese subjects [18]. Therefore, we added recombinant mouse leptin protein to the medium to indirectly mimic the physiological conditions in obesity. The cell growth and MCP-1 secretion by RAW264.7 cells were analyzed after treatment with serial doses of leptin, with or without LPS stimulation. The leptin treatments at doses 50 to 1600 ng/mL did not affect cell viability compared to the untreated control group (Fig 2A). MCP-1 secretion gently increased with an increase in leptin concentration, and the secretion was significantly high at 200 ng/mL leptin with LPS stimulation (Fig 2B). Therefore, the leptin concentration of 200 ng/mL was used as a condition for future experiments.

To investigate whether lunasin affected pro-inflammatory cytokine secretion from macrophages in obesity-related environments, RAW264.7 cells were treated with 1, 10, and 50 μM lunasin and were activated with leptin, LPS, or a combination of both, to induce an obesity-related inflammatory reaction. Leptin activation provided a mild stimulation; therefore, LPS supplement was used to enhance the inflammatory activation of RAW264.7 macrophages. In the active models, production of pro-inflammatory cytokines MCP-1, IL-6, TNF-α, and IL-1β apparently increased compared to that in non-activated cells (Fig 2C–2F). In the LPS stimulation model of RAW264.7 cells, treatments with 1, 10, and 50 μM lunasin showed a dose-dependent decrease of 14, 32, and 47%, respectively, in MCP-1 secretion (p = 0.039, p < 0.005, p < 0.005, respectively; Fig 2C) and a significant decrease of 23% in IL-6 secretion at 50 μM lunasin concentration (p = 0.017; Fig 2D). In the leptin plus LPS model, lunasin treatments (1, 10, and 50 μM) showed a dose-dependent decrease of 24, 37, and 48% in MCP-1 and 19, 18, and 28% in IL-6 secretions, respectively (p < 0.05; Fig 2C and 2D), and a significant decrease in TNF-α and IL-1β secretions at a concentration of 50 μM lunasin (p = 0.018, p = 0.024, respectively; Fig 2E and 2F). In the model with leptin alone as a stimulator, this suppressive property of lunasin was reflected only by a decrease in IL-1β secretion, which may be due to the very mild activation by leptin.
A. Obesity-related inflammatory models

RAW 264.7 cells

Leptin stimulation
Ad-CM stimulation
Co-culture with 3T3-L1 cells

Pro-inflammatory cytokines: MCP-1, IL-6, TNF-α, IL-1β

B. 

![Graph showing cell viability vs. lunasin concentration](image)

C. 

![Graph showing cell viability vs. LPS concentration](image)

D. 

![Graph showing MCP-1 production vs. LPS concentration](image)
Lunasin inhibited inflammatory cytokine production in Ad-CM-conditioned RAW264.7 cells

To evaluate the anti-inflammatory actions of lunasin in the obesity-related environment, the effects of inflammatory mediators were analyzed in the culture supernatant. Ad-CM was generated to mimic the physiology of obesity, according to a previous study [17]. In this model, RAW264.7 cells were cultured in replaced Ad-CM medium to stimulate obesity-related inflammation in the macrophages (Fig 3). The control group was defined as 0% Ad-CM, i.e., cell culture without conditioned medium. After being cultured in 10, 25, and 50% Ad-CM in the presence or absence of LPS stimulation for 24 h, the growth and MCP-1 secretion by RAW264.7 cells were analyzed. The cell viability was not affected by Ad-CM treatment (Fig 3A), but the MCP-1 secretion gently increased with increase in the dose of Ad-CM, compared to that in the control medium, especially on LPS stimulation ($p < 0.05$; Fig 3B). The middle dose of Ad-CM at 25%, which caused mild activation, was used as a condition for future in vitro experiments.

The cells were treated with 1, 10, and 50 μM lunasin and were activated by Ad-CM, LPS, or a combination of both to induce an obesity-related inflammatory reaction. Cytokine MCP-1, IL-6, TNF-α, and IL-1β productions apparently increased in active models, compared to those with use of medium alone (Fig 3). In the model with Ad-CM, the suppressive property of lunasin was reflected by decrease in MCP-1 and IL-1β secretions. MCP-1 secretion, by the cells treated with 1, 10, and 50 μM lunasin, significantly decreased by 16, 13, and 21%, respectively ($p < 0.05$; Fig 3C), and IL-1β production decreased by 18, 18, and 12%, respectively ($p = 0.015$, $p = 0.061$, $p = 0.090$, respectively; Fig 3F) compared to that in the control group. In the LPS stimulation model of RAW264.7 cells, 50 μM lunasin decreased MCP-1 secretion by 16% ($p = 0.024$; Fig 3C). Treatment with 10 and 50 μM lunasin significantly decreased the secretion of IL-6 by 34 and 32%, TNF-α by 20 and 26%, and IL-1β by 22 and 22%, respectively ($p < 0.05$; Fig 3D–3F). In the Ad-CM plus LPS model, 50 μM lunasin treatment led to decrease in MCP-1 secretion ($p = 0.017$) and significant decrease in IL-6 and IL-1β productions ($p < 0.05$; Fig 3D and 3F). In addition, it significantly decreased TNF-α secretion at all concentrations ($p < 0.005$; Fig 3E).

Lunasin disrupted the crosstalk between macrophages and adipocytes

Potential mediators of interactions between RAW264.7 cells and 3T3-L1 adipocytes were evaluated by a co-culture transwell system for 24 h (Fig 4A). The level of MCP-1 in the medium with only 3T3-L1 or RAW264.7 cells was very low, but increased by four times in the supernatant of co-culture of both cells. MCP-1 level significantly was increased by approximately 26-fold upon LPS stimulation, compared to that in the co-culture without LPS stimulation (Fig 4B). The culture supernatant was analyzed at the end of the co-culture period, and the levels of cytokines MCP-1, IL-6, TNF-α, and IL1-β were measured by ELISA. Data showed that these cytokine secretions by the cells were stimulated by LPS (Fig 4C), as these cytokine levels were not significant among groups without stimulation (data not shown). When both cell
types were present, the IL-6 production was reduced by 9% \((p < 0.05)\) on treatment with 50 \(\mu\)M lunasin, whereas a decrease in TNF-\(\alpha\) (17%) and IL-1\(\beta\) (21%) secretions was observed on 50 \(\mu\)M and 10 \(\mu\)M lunasin treatments \((p = 0.107, p = 0.081\), respectively; Fig 4C). The results of this model were not significant like those of leptin and Ad-CM models, suggesting that the co-culture system was more complicated and the culture conditions should be improved to get an appropriate response. This data also indicated that lunasin treatment blocked the production of mediators related to inflammatory reaction in the co-culture system.

**Lunasin inhibited pro-inflammatory adipokine production in 3T3-L1 adipocytes**

To evaluate the anti-inflammatory activity of lunasin on 3T3-L1 adipocytes, the effects on adipokines were analyzed. Lunasin did not affect the differentiation and lipid accumulation of 3T3-L1 adipocytes (data not shown). 3T3-L1 cells were treated with 5, 25, and 50 \(\mu\)M lunasin and were stimulated with 10 ng/mL TNF-\(\alpha\), 50% RAW-CM, or 1 \(\mu\)g/mL LPS to induce inflammatory conditions in the adipocytes (Fig 5). In the LPS stimulation model, the MCP-1 level decreased by 25% \((p = 0.022)\) and 19% \((p = 0.064)\) on treatment with 5 and 50 \(\mu\)M lunasin, respectively, whereas lunasin treatments at doses 25 and 50 \(\mu\)M significantly decreased PAI-1 level by 14 and 16% and leptin level by 38 and 56%, respectively \((p < 0.05)\), in 3T3-L1 cells, showing a dose-dependence (Fig 5B and 5C). In the RAW-CM stimulation model, PAI-1 adipokine secretion by the cells treated with 25 and 50 \(\mu\)M lunasin significantly decreased by 19 and 20%, respectively \((p < 0.05)\), in a dose-dependent manner (Fig 5B). In the TNF-\(\alpha\) stimulation model, treatment with 25 and 50 \(\mu\)M lunasin decreased leptin secretion by 18% \((p = 0.051)\) and 26% \((p = 0.007)\), respectively, compared to that in the control (Fig 5C). In contrast, adiponectin secretion increased by 15% after 50 \(\mu\)M lunasin treatment by LPS stimulation, although the difference was not significant (Fig 5D). The contrasting roles of leptin and adiponectin were indicated in the inflammatory reaction, as leptin promoted the inflammatory process, whereas adiponectin was involved in the suppression of inflammation. This suggested that lunasin might play a significant anti-inflammatory role in adipocytes.

**Discussion**

Obesity is a chronic over-nutrition disease with lipid accumulation that results in low-grade chronic inflammation in the microenvironment of adipose tissue. Accumulating evidence has revealed that various immune modifications, and pro-inflammatory cytokine overproduction around the adipose tissue resulting in the inflammatory state, are associated with adiposity [2]. This kind of inflammatory condition has been observed in the development of obesity-related diseases [4–6, 19]. This study proposed that lunasin is a promising agent with anti-inflammatory property in the obesity-related in vitro models. The obesity-related inflammatory models of macrophage were built using leptin, Ad-CM, and a co-culture system. The results suggested that lunasin works as a potential natural agent with anti-inflammatory property in both macrophages and adipocytes, and disrupts the crosstalk between the two cells.
Lunasin attenuates obesity-related inflammation

A. Cell viability (%)

B. MCP-1 (% of control)

C. MCP-1 (% of control)

D. IL-6 (% of control)

E. TNF-α (% of control)

F. IL-1β (% of control)
Leptin was first discovered owing to its role in satiety and energy homeostasis [20]. It was found that leptin level was higher in the serum of obese subjects with leptin-resistant expression compared to that of lean subjects [18]. In the past decade, multiple functions of leptin in the immune system have been revealed [21]. Leptin works as an inflammatory mediator and can activate both adaptive and innate immunities [22]. Therefore, leptin was used as an activator in the present study to investigate the physiological conditions in obesity. Although high levels of leptin are observed in obese subjects, it could not induce apparent activation of macrophages in our study. To trigger a strong inflammatory reaction, LPS was added to the leptin model, after which the anti-inflammatory effects of lunasin became apparent in lunasin-treated RAW264.7 cells.

Studies suggest that inflammasome activation, through IL-1β activation, may contribute to insulin resistance and type II diabetes [23]. IL-1β, secreted by monocytes, macrophages, and adipocytes, is a pro-inflammatory cytokine that plays an important role in the destruction of pancreatic β-cells [24]. Many studies have shown that IL-1β blockers, such as anti-IL-1β monoclonal antibody, specifically block the inflammatory signaling cascade, which provides an effective treatment for obesity-related inflammation, insulin resistance, type II diabetes, and autoimmune diseases, like type I diabetes [24, 25]. Hence, lunasin decreased IL-1β secretion after leptin activation alone, indicating that this suppression might reduce obesity-induced inflammation and metabolic complications.

Ad-CM contains inflammatory mediators secreted by adipocytes, and it has been used to mimic the physiology of obesity [17]. This medium containing a series of mediators secreted by adipocytes is thought to be closer to the physiology of obesity than the medium with leptin supplement alone. When the RAW264.7 cells were cultured in Ad-CM, cytokine MCP-1 and IL-1β levels were decreased after lunasin treatment. In a typical physiology, macrophages play an important role in the host defense and proper development of tissue. Several cytokines produced by macrophages directly act on the inflammatory processes, participating in pathogen clearance, sensing of tissue damage, and maintenance of tissue homeostasis [26].

Stimulators, such as LPS, trigger cell active signaling through toll-like receptors (TLRs) leading to infiltration and activation of macrophages involved in the innate response [2, 27]. LPS activation initiates a cascade signaling pathway of inflammatory reactions and induces oxidative stress through recognition TLR4 present on immune cells and other types of cells, such as adipocytes [28, 29]. In obesity, LPS is derived from excess nutrients, such as saturated/free fatty acids, and gut endotoxins to activate TLR4 and perhaps other TLRs, resulting in a significant inflammatory reaction and adipocyte dysfunction [30]. Mechanistically, the obesity-related inflammation includes mTOR, JAK, JNK, IKKβ, and PI3K/Akt signaling pathways involved in inflammation activation [3, 31], which contribute to increased secretion of cytokines, such as TNF-α, IL-6, and resistin, and decreased secretion of adiponectin [30]. Moreover, gut microbiota-derived endotoxins induce pro-inflammatory and pro-oxidant reactions and subsequently cause metabolic disorders in obesity mice models [29], suggesting that adiposity is associated with progression of various metabolic complications. Recently, Achek and co-workers [32] highlighted that several agents targeting TLR are in their developmental stages or clinical
A. Lunasin attenuates obesity-related inflammation

| fibroblast | differentiation | adipocyte |
|------------|----------------|-----------|
| Day -5     | Day 0-4:       | Day 4-13: |
| 3 x 10^5/well | Differentiated | Differentiated |
| DMEM/10%BS | Medium I       | Medium II |
| DMEM/10%FBS | Raw264.7       | ST3-L1    |
| Co-culture for 24h with lunasin treatment |

Supernatant for cytokine assay

B. MCP-1 (ng/mL)

3T3 | RAW | cocultrol | cocultrol-LPS

C. Cytokines (% of control)

MCP-1 | IL-6 | TNF-α | IL-1β

LPS

P = 0.107

P = 0.081
trials for related immune responses and inflammatory diseases, suggesting that LPS could be a considerable stimulator to study obesity-related inflammatory response. Pro-inflammatory cytokines were inhibited by lunasin in both Ad-CM and LPS stimulated models, reflecting that lunasin can be a promising agent might possibly by disrupting the TLR signaling.

In the past decade, the intricate interaction between obesity and immune regulation has attracted the attention of various scientists. In adiposity, excess secretion of various pro-inflammatory cytokines, chemokines, and proteases, such as TNF-α, IL-6, MCP-1, leptin, and PAI-1, by infiltrating macrophages and T cells around the adipose tissue, leads to endothelial dysfunction, oxidative stress, and inflammation activation [19, 33].

MCP-1, also known as (C-C) motif ligand 2, is a member of the chemokine superfamily that functions in the recruitment and activation of monocytes during inflammation. MCP-1 has been shown to hasten macrophage infiltration in both adiposity and cancer development [34, 35]. In addition to high levels of MCP-1, hypertrophied adipocytes also express MCP-1 receptor C-C motif chemokine receptor 2 [2]. TNF-α is a conductor cytokine, whose increased expression mediates the pathogenic process of various inflammatory diseases. It has been demonstrated that blocking TNF-α and its receptor in animal models leads to resistance to development of obesity-induced insulin resistance and it may have related benefits [25]. IL-6 is another cytokine, similar to TNF-α, overexpressed in the adipose tissue in obesity [36]. These data support that lower levels of MCP-1, IL-6, TNF-α, and IL-1β induced by lunasin might help to suppress the immune activation in obesity-induced inflammatory diseases.

Based on various researches, it has been proposed that adipose tissue dysfunction is associated with cardiovascular inflammation, insulin resistance, metabolic disorders, and carcinogenesis. Adipose tissue dysfunction in subjects with nascent metabolic syndromes leads to higher secretion of adipokines, such as IL-1, IL-6, IL-8, leptin, MCP-1, PAI-1, C-reactive protein, and serum amyloid A, by subcutaneous adipose tissue [37]. In the present study, lunasin significantly decreased MCP-1, leptin, and PAI-1 productions in 3T3-L1 adipocytes, contributing to inhibition of inflammatory mediators in this microenvironment. Leptin and adiponectin are two major adipokines secreted by adipocytes. Besides energy regulation, leptin has immune system-related roles involving immune regulation, and inflammatory response, which contribute to metabolic disorders and neoplastic cell growth [38]. The possible molecular mechanism involves generation of reactive oxygen species and expression of cyclooxygenase-2, which may trigger release of pro-inflammatory mediators through NF-κB signaling cascade [39]. In contrast, adiponectin is a negatively-regulated adipokine that is inversely associated with adiposity and inflammation. PAI-1, a serine protease inhibitor, is secreted by various cell types, including adipocytes, stromal cells, and endothelial cells, and has been associated with many pathological conditions, such as aging, cardiovascular diseases, type II diabetes, obesity, and inflammation [37]. PAI-1 shows higher expression in obese subjects and participates in adipocyte differentiation [40]. In the present study, the adiponectin level was not affected by lunasin treatment. It has demonstrated that LPS stimulation significantly reduced adiponectin and its receptor genes expression at 4 h treatment, but not at 24 h in
3T3-L1 cells [41], suggested that 24 h activation in 3T3-L1 adipocytes was too long for this mediator’s analysis. In addition, it is not always associated between adiponectin and inflammation. Onat et al. have reported the level of serum adiponectin is not significant related with inflammatory markers in Turkish adults [42]. Lunasin, a natural seed peptide, exerts many biological activities, such as anti-oxidative, anti-inflammatory, and anti-carcinogenic activities, thereby contributing to health improvement and disease prevention [10]. Currently, lunasin is being sold as a branded ingredient for promoting health, and in the past few years, its anti-cholesterol ability was revealed [43, 44]. Considering the anti-inflammatory property of lunasin, it has been shown to decrease pro-inflammatory cytokines in activated RAW264.7 cells [12], possibly through inhibition of NF-κB signaling in cardiovascular patients [13, 14], suppression of inflammatory adipokine production in 3T3-L1 adipocytes.

Fig 5. Lunasin inhibited pro-inflammatory adipokine production in 3T3-L1 adipocytes. 3T3-L1 adipocytes were treated with various doses of lunasin and were stimulated with 10 ng/mL TNF-α, 50% RAW-CM, or 1 μg/mL LPS to induce inflammatory conditions for 24 h. A. MCP-1 production was analyzed in the supernatant by ELISA. B. PAI-1 production was analyzed by ELISA. C. Leptin production was analyzed by ELISA. D. Adiponectin production was analyzed by ELISA. Data are presented as mean ± SEM from three independent experiments. Statistical analysis was based on one-way ANOVA and LSD post hoc test; *p < 0.05, or #p < 0.001 vs. control group. LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; lun, lunasin; IL, interleukin; PAI-1, plasminogen activator inhibitor-1; RAW-CM, RAW264.7 cell-conditioned medium; TNF-α, tumor necrosis factor-α.

doi:10.1371/journal.pone.0171969.g005

3T3-L1 cells [41], suggested that 24 h activation in 3T3-L1 adipocytes was too long for this mediator’s analysis. In addition, it is not always associated between adiponectin and inflammation. Onat et al. have reported the level of serum adiponectin is not significant related with inflammatory markers in Turkish adults [42]. Lunasin, a natural seed peptide, exerts many biological activities, such as anti-oxidative, anti-inflammatory, and anti-carcinogenic activities, thereby contributing to health improvement and disease prevention [10]. Currently, lunasin is being sold as a branded ingredient for promoting health, and in the past few years, its anti-cholesterol ability was revealed [43, 44]. Considering the anti-inflammatory property of lunasin, it has been shown to decrease pro-inflammatory cytokines in activated RAW264.7 cells [12], possibly through inhibition of NF-κB signaling in cardiovascular patients [13, 14], suppression of inflammatory adipokine production in 3T3-L1 adipocytes.

Fig 6. A schema of the possible influential insights on anti-inflammatory property of lunasin. In RAW264.7 macrophages, lunasin decreased inflammatory cytokine MCP-1, IL-6, TNF-α, and IL-1β productions. In 3T3-L1 adipocytes, lunasin inhibited the secretion of inflammatory adipokines MCP-1, PAI-1, and leptin. In addition, treatment with lunasin reduced the levels of these pro-inflammatory mediators, thereby disrupting the crosstalk between the two cells in a co-culture. Lunasin apparently exerted anti-inflammatory ability, possibly diminishing the obesity-induced inflammatory diseases.

doi:10.1371/journal.pone.0171969.g006
of Akt phosphorylation and p65 protein expression in activated THP-1 cells [15]. Recently, the possible molecular mechanism of lunasin has demonstrated to decrease the phosphorylation of FAK, Src, Akt, and ERK, and to inactivate the nucleus translocation of NF-κB in human breast cancer cells [45]. Moreover, lunasin inhibits inflammatory response of macrophages via intervening in endocytosis-mediated integrin signaling, increased caveolin-1 expression, and internalization by macrophages [16]. In the culture model of rheumatoid arthritis, treatment with lunasin reduced cytokine production by IL-6, IL-8, and matrix metalloproteinase-3 and suppressed NF-κB activation in synovial fibroblasts [46]. In asthma mice, lunasin effectively boosted the anti-allergy immunotherapy [11]. Recently, lunasin has been reported to suppress breast cancer cell migration in the obesity-related conditional models, indicating it blocks adipocyte-cancer cell cross-talk [47]. Based on these findings, lunasin could be used as a promising natural agent to prevent and/or treat obesity-related inflammation and disease without additional side effects. A schema proffered for the possible influential insights on lunasin in the present study is depicted (Fig 6).

Taken together, the process of obesity-related inflammation is dependent on the production, performance, and crosstalk among a set of chemokines, cytokines, and inflammatory mediators [48]. This study indicated that lunasin is not only effective against inflammatory response of RAW264.7 macrophages, but also highlights this suppressive property on 3T3-L1 adipocytes, and disrupts the crosstalk between macrophages and adipocytes, particularly by inhibiting secretion of pro-inflammatory mediators, might benefit to ameliorate obesity-induced inflammatory diseases. In the future, the in vivo animal study should be conducted to confirm the effect and safety of lunasin. New genomic and proteomic approaches, novel techniques, and cooperation among researchers are need to pursuit comprehensive understanding.

Supporting information
S1 Appendix. Raw data. All relevant raw data are within this supporting information file. (PDF)

Acknowledgments
We are indebted to Dr. B-F Lin and Dr. P-J Tsai of National Taiwan University and National Taiwan Normal University (Taipei, Taiwan) for providing us with cell lines.

Author Contributions
Conceptualization: CCH.
Formal analysis: MJC CHW.
Funding acquisition: CCH.
Investigation: MJC CHW.
Methodology: CCH.
Project administration: CCH.
Resources: CCH.
Supervision: CCH.
Visualization: MJC CHW.
Writing – original draft: CCH.
Writing – review & editing: CCH MJC CHW.

References

1. World Health Organization (WHO) Media Center, Geneva. 2015. Obesity and overweight. Facts about overweight and obesity. Available: http://www.who.int/mediacentre/factsheets/fs311/en/
2. Castoldi A, Naffah de Souza C, Câmara NO, Moraes-Vieira PM. The macrophage switch in obesity development. Front Immunol. 2016; 6:637. doi: 10.3389/fimmu.2015.00637 PMID: 26779183
3. Kalupahana NS, Moustaid-Moussa N, Claycombe KJ. Immunity as a link between obesity and insulin resistance. Mol Aspects Med. 2012; 33:26–34. doi: 10.1016/j.mam.2011.10.011 PMID: 22040698
4. Wensveen FM, Valentí S, Sestan M, Turk Wensveen T, Polić B. The "Big Bang" in obese fat: Events initiating obesity-induced adipose tissue inflammation. Eur J Immunol. 2015; 45(9):2446–2456. doi: 10.1002/eji.201545502 PMID: 26220361
5. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013; 2013:291546. doi: 10.1155/2013/291546 PMID: 24073332
6. Rose DP, Gracheck PJ, Vona-Davis L. The interactions of obesity, inflammation and insulin resistance in breast cancer. Cancers (Basel). 2015; 7(4):2147–2168.
7. Dawson DR III, Branch-Mays G, Gonzalez OA, Ebersole JL. Dietary modulation of the inflammatory cascade. Periodontol 2000. 2014; 64(1):161–197. doi: 10.1111/j.1600-0757.2012.00458.x PMID: 24320963
8. Ruiz-Canela M, Bes-Rastrollo M, Martínez-González MA. The role of dietary inflammatory index in cardiovascular disease, metabolic syndrome and mortality. Int J Mol Sci. 2016; 17(8). pii: E1265.
9. Galvez AF, de Lumen BO. A soybean cDNA encoding a chromatin-binding peptide inhibits mitosis of mammalian cells. Nat Biotechnol. 1999; 17:495–500. doi: 10.1038/8676 PMID: 10331812
10. Hernández-Ledesma B, Hsieh CC, de Lumen BO. Chemopreventive properties of peptide lunasin: a review. Protein Pept Lett. 2013; 20:424–432. PMID: 23016582
11. Yang X, Zhu J, Tung CY, Gardiner G, Wang Q, Chang HC, et al. Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs. PLoS One. 2015; 10(2):e0115330. doi: 10.1371/journal.pone.0115330 PMID: 26546897
12. Hernández-Ledesma B, Hsieh CC, de Lumen BO. Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW264.7 macrophages. Biochem Biophys Res Commun. 2009; 390:803–808. doi: 10.1016/j.bbrc.2009.10.053 PMID: 19836349
13. de Mejía EG, Dia VP. Lunasin and lunasin-like peptides inhibit inflammation through suppression of NF-κB pathway in the macrophage. Peptides. 2009; 30:2388–2398. doi: 10.1016/j.peptides.2009.08.005 PMID: 19682518
14. Dia VP, Wang W, Oh VL, de Lumen BO, de Mejía EG. Isolation, purification and characterisation of lunasin from defatted soybean flour and in vitro evaluation of its anti-inflammatory activity. Food Chem. 2009; 114:108–115.
15. Cam A, de Mejía E. RGD-peptide lunasin inhibits Akt-mediated NF-κB activation in human macrophages through interaction with the αVβ3 integrin. Mol Nutr Food Res. 2012; 56:1569–1581. doi: 10.1002/mnfr.201200301 PMID: 22945510
16. Cam A, Sivaguru M, de Mejía EG. Endocytic mechanism of internalization of dietary peptide lunasin into macrophages in inflammatory condition associated with cardiovascular disease. PLoS One. 2013; 8(9):e72115. doi: 10.1371/journal.pone.0072115 PMID: 24039740
17. Hsieh CC, Huang YS. Aspirin breaks the crosstalk between 3T3-L1 adipocytes and 4T1 breast cancer cells by regulating cytokine production. PLoS One. 2016; 11(1):e0147161. doi: 10.1371/journal.pone.0147161 PMID: 26794215
18. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998; 395:763–770. doi: 10.1038/27376 PMID: 9796811
19. Aroor AR, McMacks S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism. 2013; 62(11):1543–1552. doi: 10.1016/j.metabol.2013.07.001 PMID: 23932846
20. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Sunwit RS. Role of leptin in fat regulation. Nature. 1996; 380:677. doi: 10.1038/380677a0 PMID: 8614460
21. Procaccini C, De Rosa V, Gaigani M, Carbone F, La Rocca C. Role of adipokines signaling in the modulation of T cells function. Front Immunol. 2013; 4:332. doi: 10.3389/fimmu.2013.00332 PMID: 24151494
22. Naylor C, Petri WA Jr. Leptin regulation of immune responses. Trends Mol Med. 2016; 22(2):88–98. doi: 10.1016/j.molmed.2015.12.001 PMID: 26776093
23. Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG. The inflammasome puts obesity in the danger zone. Cell Metab. 2012; 15:10–18. doi: 10.1016/j.cmet.2011.10.001 PMID: 22225872

24. Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance. Cyto- kine. 2015; 75(2):280–290. doi: 10.1016/j.cyto.2015.05.005 PMID: 26194067

25. Andrade-Oliveira V, Cârmar NO, Moraes-Vieira PM. Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res. 2015; 2015:681612. doi: 10.1155/2015/681612 PMID: 25918733

26. Sica A, Erreni M, Allavena P, Porta C. Macrophage polarization in pathology. Cell Mol Life Sci. 2015; 72 (21):4111–4126. doi: 10.1007/s00018-015-1995-y PMID: 26210152

27. Dam V, Sikder T, Santos A. From neutrophils to macrophages: differences in regional adipose tissue depots. Obes Rev. 2016; 17(1):1–17. doi: 10.1111/obr.12335 PMID: 26667065

28. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun. 2006; 346(3):739–745. doi: 10.1016/j.bbrc.2006.05.170 PMID: 16781673

29. Boutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxicemia with obesity: Is it real and is it relevant? Biochimie. 2016; 124:11–20. doi: 10.1016/j.bioch.2015.06.020 PMID: 26133659

30. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34:39–58. doi: 10.1016/j.mam.2012.11.001 PMID: 23159341

31. Patel PS, Buras ED, Balasubramanyam A. The role of the immune system in obesity and insulin resistance. J Obes. 2013; 2013:616193. doi: 10.1155/2013/616193 PMID: 23577240

32. Achek A, Yesudhas D, Choi S. Toll-like receptors: promising therapeutic targets for inflammatory diseases. Arch Pharm Res. 2016; 39(8):1032–1049. doi: 10.1007/s12272-016-0806-9 PMID: 27515048

33. Strong AL, Burow ME, Gimble JM, Bunnell BA. Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells. Stem Cells. 2015; 33(2):318–326. doi: 10.1002/stem.1857 PMID: 25267443

34. Li M, Knight DA, L AS, Smyth MJ, Stewart TJ. A role for CCL2 in both tumor progression and immuno-surveillance. Oncology. 2013; 2; e25474. doi: 10.4161/onc.25474 PMID: 24073384

35. Panee J. Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012; 60:1–9. doi: 10.1016/j.cyto.2012.06.018 PMID: 22766373

36. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumour necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001; 280:E745–751.

37. Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes. 2013; 2013:393192. doi: 10.1155/2013/393192 PMID: 23653857

38. Delort L, Rossary A, Farges MC, Vasson MP, Caldefie-Chezet F. Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity. Life Sci. 2015; 140:37–48. doi: 10.1016/j.lfs.2015.04.05.170 PMID: 26133659

39. Tian YF, Chang WC, Loh CH, Hsieh PS. Leptin-mediated inflammatory signaling crucially links visceral fat inflammation to obesity-associated beta-cell dysfunction. Life Sci. 2014; 116:51–58. doi: 10.1016/j.lfs.2014.07.039 PMID: 25123537

40. Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6:772–783. doi: 10.1038/nri1937 PMID: 16998510

41. Hall A, Leuwer M, Trayhurn P, Welsits ID. Lipopolysaccharide induces a downregulation of adiponectin receptors in-vitro and in-vivo. Peer J. 2015; 3:e1428. doi: 10.7717/peerj.1428 PMID: 26618091

42. Onat A, Hergenç G, Dursunolu D, Kıcıküçürmaz Z, Bulur S, Can G. Relatively high levels of serum adiponectin in obese women, a potential indicator of anti-inflammatory dysfunction: relation to sex hormone-binding globulin. Int J Biol Sci. 2008, 4:208–214. PMID: 18695734

43. Galvez AF. Abstract 10693: Identification of lunasin as the active component in soy protein responsible for reducing LDL cholesterol and risk of cardiovascular disease. Circulation. 2012; 126(Suppl 21): A10693-A. Available: http://circ.ahajournals.org/content/126/Suppl_21/A10693

44. Galvez AF, Matel H, Ivey J, Bowles D. Lunasin-enriched soy extract (LunaRich X™), in combination with the dietary supplement Reliv Now, reduces free fatty acid by increasing plasma leptin and adiponectin levels in LDL-receptor mutant pigs. 2013, PRWEB [Internet]. Available: http://www.prweb.com/releases/lunasinlunarichxrelivnow/nutritionalalepigenetics/prweb11137975.htm

45. Jiang Q, Pan Y, Cheng Y, Li H, Liu D, Li H. Lunasin suppresses the migration and invasion of breast cancer cells by inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-κB signaling pathways. Oncol Rep. 2016; 36(1):253–262. doi: 10.3892/or.2016.4798 PMID: 27175819
46. Jia S, Zhang S, Yuan H, Chen N. Lunasin inhibits cell proliferation via apoptosis and reduces the production of proinflammatory cytokines in cultured rheumatoid arthritis synovial fibroblasts. Biomed Res Int. 2015; 2015:346839. doi: 10.1155/2015/346839 PMID: 25692134

47. Hsieh CC, Wang CH, Huang YS. Lunasin attenuates obesity-associated metastasis of 4T1 breast cancer cell through anti-inflammatory property. Int J Mol Sci. 2016; 17(12). pii: E2109.

48. Apostolopoulos V, de Courten MP, Stojanovska L, Blatch GL, Tangalakis K, de Courten B. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res. 2016; 60 (1):43–57. doi: 10.1002/mnfr.201500272 PMID: 26331761